User login
Ambition linked to increased creativity in bipolar patients
Heightened ambition seems to be an important aspect of increased creativity in people with bipolar disorder, according to results of two studies by Sheri L. Johnson, Ph.D., and her associates.
In Study One, 22 bipolar patients who identified as highly creative took the WASSUP (Willingly Approached Set of Statistically Unlikely Pursuits) test, an assessment to determine ambition. WASSUP scores were elevated in the group, and a higher score was related to lifetime creative accomplishment in artistic bipolar patients.
In Study Two, 221 undergraduates completed the WASSUP, the Hypomanic Personality Scale (to measure mania risk), and a measure to assess creativity in business projects. Both increased ambition and creativity were linked to increased mania risk, and ambition was related to creativity outside of a bipolar setting as well.
Find the study in the Journal of Affective Disorders (doi: 10.1016/j.jad.2015.02.021).
Heightened ambition seems to be an important aspect of increased creativity in people with bipolar disorder, according to results of two studies by Sheri L. Johnson, Ph.D., and her associates.
In Study One, 22 bipolar patients who identified as highly creative took the WASSUP (Willingly Approached Set of Statistically Unlikely Pursuits) test, an assessment to determine ambition. WASSUP scores were elevated in the group, and a higher score was related to lifetime creative accomplishment in artistic bipolar patients.
In Study Two, 221 undergraduates completed the WASSUP, the Hypomanic Personality Scale (to measure mania risk), and a measure to assess creativity in business projects. Both increased ambition and creativity were linked to increased mania risk, and ambition was related to creativity outside of a bipolar setting as well.
Find the study in the Journal of Affective Disorders (doi: 10.1016/j.jad.2015.02.021).
Heightened ambition seems to be an important aspect of increased creativity in people with bipolar disorder, according to results of two studies by Sheri L. Johnson, Ph.D., and her associates.
In Study One, 22 bipolar patients who identified as highly creative took the WASSUP (Willingly Approached Set of Statistically Unlikely Pursuits) test, an assessment to determine ambition. WASSUP scores were elevated in the group, and a higher score was related to lifetime creative accomplishment in artistic bipolar patients.
In Study Two, 221 undergraduates completed the WASSUP, the Hypomanic Personality Scale (to measure mania risk), and a measure to assess creativity in business projects. Both increased ambition and creativity were linked to increased mania risk, and ambition was related to creativity outside of a bipolar setting as well.
Find the study in the Journal of Affective Disorders (doi: 10.1016/j.jad.2015.02.021).
New atypical antipsychotic FDA approved for use in bipolar I and schizophrenia
The Food and Drug Administration on Sept. 17 approved cariprazine, an atypical antipsychotic, for the acute treatment of manic or mixed episodes in bipolar I disorder and schizophrenia in adults.
Results from three separate controlled trials in adults with manic or mixed episodes of bipolar I disorder showed cariprazine (Vraylar) was associated with improved total scores on the Young Mania Rating Scale (YMRS), compared with placebo. In three separate placebo-controlled trials in adults with schizophrenia, the study drug was associated with improvements in Positive and Negative Syndrome Scale (PANSS) total scores, compared with placebo. Cariprazine also demonstrated efficacy in the Clinical Global Impressions–Severity (CGI-S) rating scale, which was the secondary efficacy endpoint in the respective trials for each condition. In all, 2,700 persons were enrolled in the trials.
The recommended dose of cariprazine in adults with bipolar I is once daily at 3-6 mg per day. For schizophrenia in adults, 1.5-6 mg/day is the recommended dose.
Adverse reactions occurring in at least 5% of the study population and at a rate of twice that in the placebo groups were extrapyramidal symptoms, akathisia, dyspepsia, vomiting, somnolence, and restlessness in the bipolar group. In the group with schizophrenia, the most commonly reported adverse events were extrapyramidal symptoms and akathisia.
Cariprazine is a dopamine-2 and dopamine-3 receptor partial agonist, tending toward the D3 receptor. Although its mechanism of action in schizophrenia and bipolar I disorder is unknown, the drug’s codeveloper, Gedeon Richter said in a statement that cariprazine’s efficacy “could be mediated through a combination of partial agonist activity at central D2 and serotonin 5-HT1A receptors and antagonist activity at serotonin 5-HT2A receptors.” In the United States and Canada, the drug is licensed to Actavis, now Allergan. Vraylar is manufactured by Forest Laboratories.
Data indicating the drug’s ability to improve flat affect in schizophrenia were presented at this year’s annual congress of the European College of Neuropsychopharmacology in Amsterdam. According to Gedeon Richter and Allergan, cariprazine also is being investigated for the treatment of bipolar depression and as adjunctive treatment for major depressive disorder in adults.
On Twitter @whitneymcknight
*This article was updated 9/18/2015.
The Food and Drug Administration on Sept. 17 approved cariprazine, an atypical antipsychotic, for the acute treatment of manic or mixed episodes in bipolar I disorder and schizophrenia in adults.
Results from three separate controlled trials in adults with manic or mixed episodes of bipolar I disorder showed cariprazine (Vraylar) was associated with improved total scores on the Young Mania Rating Scale (YMRS), compared with placebo. In three separate placebo-controlled trials in adults with schizophrenia, the study drug was associated with improvements in Positive and Negative Syndrome Scale (PANSS) total scores, compared with placebo. Cariprazine also demonstrated efficacy in the Clinical Global Impressions–Severity (CGI-S) rating scale, which was the secondary efficacy endpoint in the respective trials for each condition. In all, 2,700 persons were enrolled in the trials.
The recommended dose of cariprazine in adults with bipolar I is once daily at 3-6 mg per day. For schizophrenia in adults, 1.5-6 mg/day is the recommended dose.
Adverse reactions occurring in at least 5% of the study population and at a rate of twice that in the placebo groups were extrapyramidal symptoms, akathisia, dyspepsia, vomiting, somnolence, and restlessness in the bipolar group. In the group with schizophrenia, the most commonly reported adverse events were extrapyramidal symptoms and akathisia.
Cariprazine is a dopamine-2 and dopamine-3 receptor partial agonist, tending toward the D3 receptor. Although its mechanism of action in schizophrenia and bipolar I disorder is unknown, the drug’s codeveloper, Gedeon Richter said in a statement that cariprazine’s efficacy “could be mediated through a combination of partial agonist activity at central D2 and serotonin 5-HT1A receptors and antagonist activity at serotonin 5-HT2A receptors.” In the United States and Canada, the drug is licensed to Actavis, now Allergan. Vraylar is manufactured by Forest Laboratories.
Data indicating the drug’s ability to improve flat affect in schizophrenia were presented at this year’s annual congress of the European College of Neuropsychopharmacology in Amsterdam. According to Gedeon Richter and Allergan, cariprazine also is being investigated for the treatment of bipolar depression and as adjunctive treatment for major depressive disorder in adults.
On Twitter @whitneymcknight
*This article was updated 9/18/2015.
The Food and Drug Administration on Sept. 17 approved cariprazine, an atypical antipsychotic, for the acute treatment of manic or mixed episodes in bipolar I disorder and schizophrenia in adults.
Results from three separate controlled trials in adults with manic or mixed episodes of bipolar I disorder showed cariprazine (Vraylar) was associated with improved total scores on the Young Mania Rating Scale (YMRS), compared with placebo. In three separate placebo-controlled trials in adults with schizophrenia, the study drug was associated with improvements in Positive and Negative Syndrome Scale (PANSS) total scores, compared with placebo. Cariprazine also demonstrated efficacy in the Clinical Global Impressions–Severity (CGI-S) rating scale, which was the secondary efficacy endpoint in the respective trials for each condition. In all, 2,700 persons were enrolled in the trials.
The recommended dose of cariprazine in adults with bipolar I is once daily at 3-6 mg per day. For schizophrenia in adults, 1.5-6 mg/day is the recommended dose.
Adverse reactions occurring in at least 5% of the study population and at a rate of twice that in the placebo groups were extrapyramidal symptoms, akathisia, dyspepsia, vomiting, somnolence, and restlessness in the bipolar group. In the group with schizophrenia, the most commonly reported adverse events were extrapyramidal symptoms and akathisia.
Cariprazine is a dopamine-2 and dopamine-3 receptor partial agonist, tending toward the D3 receptor. Although its mechanism of action in schizophrenia and bipolar I disorder is unknown, the drug’s codeveloper, Gedeon Richter said in a statement that cariprazine’s efficacy “could be mediated through a combination of partial agonist activity at central D2 and serotonin 5-HT1A receptors and antagonist activity at serotonin 5-HT2A receptors.” In the United States and Canada, the drug is licensed to Actavis, now Allergan. Vraylar is manufactured by Forest Laboratories.
Data indicating the drug’s ability to improve flat affect in schizophrenia were presented at this year’s annual congress of the European College of Neuropsychopharmacology in Amsterdam. According to Gedeon Richter and Allergan, cariprazine also is being investigated for the treatment of bipolar depression and as adjunctive treatment for major depressive disorder in adults.
On Twitter @whitneymcknight
*This article was updated 9/18/2015.
Executive attention deficits often persist in euthymic bipolar disorder
Euthymic bipolar disorder patients have impaired executive control (greater interference), reduced vigilance, slower overall reaction times, and poorer accuracy scores compared with healthy controls, a recent research article shows.
Lead author Andrea Marotta, Ph.D., of the University of Rome, and colleagues compared a sample of euthymic bipolar disorder patients and age-matched healthy controls, and had both groups complete the Attention Network Test for Interactions and Vigilance (ANTI-V), a neurocognitive test that assesses the efficiency of attentional networks and measures orienting, executive and alerting networks, and vigilance (tonic alerting). Although the bipolar disorder patients exhibited normal phasic alerting and orienting, they performed worse on alerting and executive control, the authors found.
“Our results show that deficits in executive attention and sustained attention often persist in [bipolar disorder] patients even after complete remission of affective symptoms, thus suggesting that cognitive enhancing treatments programmed to improve these deficits could contribute to improve their functional recovery,” they wrote.
Read the full article in Psychiatry Research (2015 Sept 30;229[1-2]:490-6. doi: 10.1016/jpsychres.2015.06.026).
Euthymic bipolar disorder patients have impaired executive control (greater interference), reduced vigilance, slower overall reaction times, and poorer accuracy scores compared with healthy controls, a recent research article shows.
Lead author Andrea Marotta, Ph.D., of the University of Rome, and colleagues compared a sample of euthymic bipolar disorder patients and age-matched healthy controls, and had both groups complete the Attention Network Test for Interactions and Vigilance (ANTI-V), a neurocognitive test that assesses the efficiency of attentional networks and measures orienting, executive and alerting networks, and vigilance (tonic alerting). Although the bipolar disorder patients exhibited normal phasic alerting and orienting, they performed worse on alerting and executive control, the authors found.
“Our results show that deficits in executive attention and sustained attention often persist in [bipolar disorder] patients even after complete remission of affective symptoms, thus suggesting that cognitive enhancing treatments programmed to improve these deficits could contribute to improve their functional recovery,” they wrote.
Read the full article in Psychiatry Research (2015 Sept 30;229[1-2]:490-6. doi: 10.1016/jpsychres.2015.06.026).
Euthymic bipolar disorder patients have impaired executive control (greater interference), reduced vigilance, slower overall reaction times, and poorer accuracy scores compared with healthy controls, a recent research article shows.
Lead author Andrea Marotta, Ph.D., of the University of Rome, and colleagues compared a sample of euthymic bipolar disorder patients and age-matched healthy controls, and had both groups complete the Attention Network Test for Interactions and Vigilance (ANTI-V), a neurocognitive test that assesses the efficiency of attentional networks and measures orienting, executive and alerting networks, and vigilance (tonic alerting). Although the bipolar disorder patients exhibited normal phasic alerting and orienting, they performed worse on alerting and executive control, the authors found.
“Our results show that deficits in executive attention and sustained attention often persist in [bipolar disorder] patients even after complete remission of affective symptoms, thus suggesting that cognitive enhancing treatments programmed to improve these deficits could contribute to improve their functional recovery,” they wrote.
Read the full article in Psychiatry Research (2015 Sept 30;229[1-2]:490-6. doi: 10.1016/jpsychres.2015.06.026).
FROM PSYCHIATRY RESEARCH
Study: Bipolar mothers’ interaction with infants weaker than unipolar mothers’
Maternal-infant interaction was worse when mothers had bipolar depression, compared with when mothers had unipolar depression or no depression, according to a study.
The study’s participants included 40 women with bipolar disorder, 50 women with a unipolar major depressive disorder, and 40 women without a major mood disorder. Researchers observed and videotaped the mothers interacting with their babies, when the mothers were 12 months post partum. Four research assistants separately assessed the interactions of each mother-baby pair, using the following four observational instruments: the Ainsworth Maternal Sensitivity Scale (AMSS), the Maternal Behavior Q-Sort (MBQS), the Dyadic Mini Code (DMC), and the Child-Caregiver Mutual Regulation Scale (CCMR). The research assistants were unaware of each mother’s depression and treatment statuses.
Women with bipolar disorder had lower scores related to maternal-infant interaction on the AMSS, DMC, and MBQS, compared with women without depression or with unipolar depression. Measures of maternal sensitivity (AMSS, MBQS) and maternal-infant synchrony (DMC) also were lower in the women with bipolar depression.
“Although there was a trend for measures of both maternal sensitivity (especially the AMSS) and maternal-infant synchrony to be lower in women with bipolar depression, the differences were not significant,” reported M. Cynthia Logsdon, Ph.D., of the University of Louisville (Ky.), and her colleagues.
Studies on maternal-infant interaction at earlier postpartum periods are needed, according to the researchers.
Read the full study here: (Appl Nurs Res. 2015;28:381-3. doi:10.1016/j.apnr.2015.01.012).
Maternal-infant interaction was worse when mothers had bipolar depression, compared with when mothers had unipolar depression or no depression, according to a study.
The study’s participants included 40 women with bipolar disorder, 50 women with a unipolar major depressive disorder, and 40 women without a major mood disorder. Researchers observed and videotaped the mothers interacting with their babies, when the mothers were 12 months post partum. Four research assistants separately assessed the interactions of each mother-baby pair, using the following four observational instruments: the Ainsworth Maternal Sensitivity Scale (AMSS), the Maternal Behavior Q-Sort (MBQS), the Dyadic Mini Code (DMC), and the Child-Caregiver Mutual Regulation Scale (CCMR). The research assistants were unaware of each mother’s depression and treatment statuses.
Women with bipolar disorder had lower scores related to maternal-infant interaction on the AMSS, DMC, and MBQS, compared with women without depression or with unipolar depression. Measures of maternal sensitivity (AMSS, MBQS) and maternal-infant synchrony (DMC) also were lower in the women with bipolar depression.
“Although there was a trend for measures of both maternal sensitivity (especially the AMSS) and maternal-infant synchrony to be lower in women with bipolar depression, the differences were not significant,” reported M. Cynthia Logsdon, Ph.D., of the University of Louisville (Ky.), and her colleagues.
Studies on maternal-infant interaction at earlier postpartum periods are needed, according to the researchers.
Read the full study here: (Appl Nurs Res. 2015;28:381-3. doi:10.1016/j.apnr.2015.01.012).
Maternal-infant interaction was worse when mothers had bipolar depression, compared with when mothers had unipolar depression or no depression, according to a study.
The study’s participants included 40 women with bipolar disorder, 50 women with a unipolar major depressive disorder, and 40 women without a major mood disorder. Researchers observed and videotaped the mothers interacting with their babies, when the mothers were 12 months post partum. Four research assistants separately assessed the interactions of each mother-baby pair, using the following four observational instruments: the Ainsworth Maternal Sensitivity Scale (AMSS), the Maternal Behavior Q-Sort (MBQS), the Dyadic Mini Code (DMC), and the Child-Caregiver Mutual Regulation Scale (CCMR). The research assistants were unaware of each mother’s depression and treatment statuses.
Women with bipolar disorder had lower scores related to maternal-infant interaction on the AMSS, DMC, and MBQS, compared with women without depression or with unipolar depression. Measures of maternal sensitivity (AMSS, MBQS) and maternal-infant synchrony (DMC) also were lower in the women with bipolar depression.
“Although there was a trend for measures of both maternal sensitivity (especially the AMSS) and maternal-infant synchrony to be lower in women with bipolar depression, the differences were not significant,” reported M. Cynthia Logsdon, Ph.D., of the University of Louisville (Ky.), and her colleagues.
Studies on maternal-infant interaction at earlier postpartum periods are needed, according to the researchers.
Read the full study here: (Appl Nurs Res. 2015;28:381-3. doi:10.1016/j.apnr.2015.01.012).
FROM APPLIED NURSING RESEARCH
Mobile interventions helpful for bipolar disorder in short term
An automated mobile phone intervention is a feasible method for symptom self-management and might enhance the impact of brief psychoeducation on depressive symptoms in bipolar disorder, according to a study in the Journal of Affective Disorders.
However, once stopped, sustainment of gains might be limited, noted Dr. Colin A. Depp of the University of California, San Diego, and his associates. They organized a randomized single-blind controlled trial with 82 people diagnosed with bipolar disorder. The individuals completed a four-session psychoeducational intervention and were assigned to 10 weeks of either mobile device–delivered interactive intervention linking patient-reported mood states with personalized self-management strategies, or paper-and-pencil mood monitoring.
Participants were assessed at baseline, 6 weeks, 12 weeks, and 24 weeks, and the researchers gathered data based on clinician-rated depression and mania scales and self-reported functioning. Retention at 12 weeks was 93% (J Affect Disord. 2015 Mar 15;174:23-30).
Compared with the paper-and-pencil condition group, participants in the augmented mobile intervention group showed significantly greater reductions in depressive symptoms at 6 and 12 weeks (Cohen’s d for both were d = 0.48). However, those effects were not maintained at the 24- week follow-up, suggesting that mobile intervention was not enough to sustain the gains after treatment ended.
Read the full article here: (doi: 10.1016/j.jad.2014.10.053).
An automated mobile phone intervention is a feasible method for symptom self-management and might enhance the impact of brief psychoeducation on depressive symptoms in bipolar disorder, according to a study in the Journal of Affective Disorders.
However, once stopped, sustainment of gains might be limited, noted Dr. Colin A. Depp of the University of California, San Diego, and his associates. They organized a randomized single-blind controlled trial with 82 people diagnosed with bipolar disorder. The individuals completed a four-session psychoeducational intervention and were assigned to 10 weeks of either mobile device–delivered interactive intervention linking patient-reported mood states with personalized self-management strategies, or paper-and-pencil mood monitoring.
Participants were assessed at baseline, 6 weeks, 12 weeks, and 24 weeks, and the researchers gathered data based on clinician-rated depression and mania scales and self-reported functioning. Retention at 12 weeks was 93% (J Affect Disord. 2015 Mar 15;174:23-30).
Compared with the paper-and-pencil condition group, participants in the augmented mobile intervention group showed significantly greater reductions in depressive symptoms at 6 and 12 weeks (Cohen’s d for both were d = 0.48). However, those effects were not maintained at the 24- week follow-up, suggesting that mobile intervention was not enough to sustain the gains after treatment ended.
Read the full article here: (doi: 10.1016/j.jad.2014.10.053).
An automated mobile phone intervention is a feasible method for symptom self-management and might enhance the impact of brief psychoeducation on depressive symptoms in bipolar disorder, according to a study in the Journal of Affective Disorders.
However, once stopped, sustainment of gains might be limited, noted Dr. Colin A. Depp of the University of California, San Diego, and his associates. They organized a randomized single-blind controlled trial with 82 people diagnosed with bipolar disorder. The individuals completed a four-session psychoeducational intervention and were assigned to 10 weeks of either mobile device–delivered interactive intervention linking patient-reported mood states with personalized self-management strategies, or paper-and-pencil mood monitoring.
Participants were assessed at baseline, 6 weeks, 12 weeks, and 24 weeks, and the researchers gathered data based on clinician-rated depression and mania scales and self-reported functioning. Retention at 12 weeks was 93% (J Affect Disord. 2015 Mar 15;174:23-30).
Compared with the paper-and-pencil condition group, participants in the augmented mobile intervention group showed significantly greater reductions in depressive symptoms at 6 and 12 weeks (Cohen’s d for both were d = 0.48). However, those effects were not maintained at the 24- week follow-up, suggesting that mobile intervention was not enough to sustain the gains after treatment ended.
Read the full article here: (doi: 10.1016/j.jad.2014.10.053).
FROM THE JOURNAL OF AFFECTIVE DISORDERS
Bipolar patients can be identified using ‘rule of three’
Dr. Hagop S. Akiskal’s “rule of three” conceptualization, which identified behavioral markers tied to bipolarity, proved effective in evaluating and differentiating patients with bipolar disorder from those with unipolar depression, according to Dr. Diogo R. Lara and his associates.
A univariate analysis of more than 70,000 samples found 29 behavioral markers significantly differentiated bipolar patients from patients with unipolar depression. Of these 29, 10 markers had odds ratios greater than 4 for bipolarity.
In a multivariate analysis, 11 markers differentiating bipolar from unipolar depression were confirmed, including reversed circadian rhythms and high debts for both genders; 3 or more provoked car accidents and talent for poetry in men; frequent book reading; 3 or more religion changes; 60 or more sexual partners; experiencing pathological love 2 or more times; heavy cursing; and extravagant dressing styles in women; found Dr. Lara of the Pontifíícia Universidade Católica do Rio Grande do Sul in Porto Alegre, Brazil, and his associates.
“Most behaviors were expressed in a minority of patients (usually 5%-30%) and usually the ‘rule of three’ was the best numerical marker to distinguish those with bipolarity,” the investigators noted.
Find the full study here: J Affect Disord. 2015 Sept 1;183:195-204. doi: 10.1016/j.jad.2015.04.046).
Dr. Hagop S. Akiskal’s “rule of three” conceptualization, which identified behavioral markers tied to bipolarity, proved effective in evaluating and differentiating patients with bipolar disorder from those with unipolar depression, according to Dr. Diogo R. Lara and his associates.
A univariate analysis of more than 70,000 samples found 29 behavioral markers significantly differentiated bipolar patients from patients with unipolar depression. Of these 29, 10 markers had odds ratios greater than 4 for bipolarity.
In a multivariate analysis, 11 markers differentiating bipolar from unipolar depression were confirmed, including reversed circadian rhythms and high debts for both genders; 3 or more provoked car accidents and talent for poetry in men; frequent book reading; 3 or more religion changes; 60 or more sexual partners; experiencing pathological love 2 or more times; heavy cursing; and extravagant dressing styles in women; found Dr. Lara of the Pontifíícia Universidade Católica do Rio Grande do Sul in Porto Alegre, Brazil, and his associates.
“Most behaviors were expressed in a minority of patients (usually 5%-30%) and usually the ‘rule of three’ was the best numerical marker to distinguish those with bipolarity,” the investigators noted.
Find the full study here: J Affect Disord. 2015 Sept 1;183:195-204. doi: 10.1016/j.jad.2015.04.046).
Dr. Hagop S. Akiskal’s “rule of three” conceptualization, which identified behavioral markers tied to bipolarity, proved effective in evaluating and differentiating patients with bipolar disorder from those with unipolar depression, according to Dr. Diogo R. Lara and his associates.
A univariate analysis of more than 70,000 samples found 29 behavioral markers significantly differentiated bipolar patients from patients with unipolar depression. Of these 29, 10 markers had odds ratios greater than 4 for bipolarity.
In a multivariate analysis, 11 markers differentiating bipolar from unipolar depression were confirmed, including reversed circadian rhythms and high debts for both genders; 3 or more provoked car accidents and talent for poetry in men; frequent book reading; 3 or more religion changes; 60 or more sexual partners; experiencing pathological love 2 or more times; heavy cursing; and extravagant dressing styles in women; found Dr. Lara of the Pontifíícia Universidade Católica do Rio Grande do Sul in Porto Alegre, Brazil, and his associates.
“Most behaviors were expressed in a minority of patients (usually 5%-30%) and usually the ‘rule of three’ was the best numerical marker to distinguish those with bipolarity,” the investigators noted.
Find the full study here: J Affect Disord. 2015 Sept 1;183:195-204. doi: 10.1016/j.jad.2015.04.046).
FROM THE JOURNAL OF AFFECTIVE DISORDERS
Metabolic dysfunction markers found in bipolar patients
Bipolar disorder patients had different levels of some of the biomarkers linked to metabolic dysfunction than healthy controls, according to a study.
The study’s participants included 57 bipolar disorder patients and a control group of 49 healthy individuals. Among the experimental group, 24 had bipolar disorder type I and the remaining 33 had bipolar disorder type II. The bipolar patients’ average duration of illness was 22 years and their average body mass index was 25.9 kg/m2. The experimental group’s ages and body mass indices were not significantly different from those of the control group.
The researchers compared the bipolar disorder patients’ and control group’s average levels of the biomarkers: C-peptide, ghrelin, glucose-dependent insulinotropic peptide (GIP), glucagonlike peptide-1 (GLP-1), glucagon, insulin, leptin, plasminogen activator inhibitor-1 (PAI-1, total), resistin, and visfatin.
Bipolar disorder patients has significantly lower levels of ghrelin, glucagon, and GLP-1 (P = .018 for ghrelin; P less than .0001 for glucagon; P less than .0001 for GLP-1), and significantly higher levels of GIP than did controls (P less than .0001).
When the bipolar I patients’ biomarker levels were compared with those of the bipolar II patients, no significant differences were found.
Additional findings included negative correlations between a patient’s level of glucagon and numbers of previous manic (r = –0.480; P less than .001), depressive (r = –0.294; P = .026), and any mood episodes (r = –0.403; P = .002). GLP-1 levels also were negatively correlated with the numbers of manic (r = –0.322; P = .015) and any mood episodes (r = –0.274 ; P = .039) experienced by a patient.
“Our findings support the hypothesis that dysregulations in serum glucagon, GLP-1, GIP, and ghrelin might be involved in [bipolar disorder] pathogenesis, particularly in the depressed phase. Moreover, the correlation of glucagon and GLP-1 alterations with number of mood episode recurrences could contribute to the identification of late-stage” bipolar disorder patients, according to Gianluca Rosso, Ph.D., of the University of Torino, Italy, and his colleagues. “Studies in larger samples are needed to confirm these data and to further investigate the common mechanism between mood and metabolic disorders.”
Read the full article here: (J Affect Disord. 2015 Sept 15;184:293-8.)
Bipolar disorder patients had different levels of some of the biomarkers linked to metabolic dysfunction than healthy controls, according to a study.
The study’s participants included 57 bipolar disorder patients and a control group of 49 healthy individuals. Among the experimental group, 24 had bipolar disorder type I and the remaining 33 had bipolar disorder type II. The bipolar patients’ average duration of illness was 22 years and their average body mass index was 25.9 kg/m2. The experimental group’s ages and body mass indices were not significantly different from those of the control group.
The researchers compared the bipolar disorder patients’ and control group’s average levels of the biomarkers: C-peptide, ghrelin, glucose-dependent insulinotropic peptide (GIP), glucagonlike peptide-1 (GLP-1), glucagon, insulin, leptin, plasminogen activator inhibitor-1 (PAI-1, total), resistin, and visfatin.
Bipolar disorder patients has significantly lower levels of ghrelin, glucagon, and GLP-1 (P = .018 for ghrelin; P less than .0001 for glucagon; P less than .0001 for GLP-1), and significantly higher levels of GIP than did controls (P less than .0001).
When the bipolar I patients’ biomarker levels were compared with those of the bipolar II patients, no significant differences were found.
Additional findings included negative correlations between a patient’s level of glucagon and numbers of previous manic (r = –0.480; P less than .001), depressive (r = –0.294; P = .026), and any mood episodes (r = –0.403; P = .002). GLP-1 levels also were negatively correlated with the numbers of manic (r = –0.322; P = .015) and any mood episodes (r = –0.274 ; P = .039) experienced by a patient.
“Our findings support the hypothesis that dysregulations in serum glucagon, GLP-1, GIP, and ghrelin might be involved in [bipolar disorder] pathogenesis, particularly in the depressed phase. Moreover, the correlation of glucagon and GLP-1 alterations with number of mood episode recurrences could contribute to the identification of late-stage” bipolar disorder patients, according to Gianluca Rosso, Ph.D., of the University of Torino, Italy, and his colleagues. “Studies in larger samples are needed to confirm these data and to further investigate the common mechanism between mood and metabolic disorders.”
Read the full article here: (J Affect Disord. 2015 Sept 15;184:293-8.)
Bipolar disorder patients had different levels of some of the biomarkers linked to metabolic dysfunction than healthy controls, according to a study.
The study’s participants included 57 bipolar disorder patients and a control group of 49 healthy individuals. Among the experimental group, 24 had bipolar disorder type I and the remaining 33 had bipolar disorder type II. The bipolar patients’ average duration of illness was 22 years and their average body mass index was 25.9 kg/m2. The experimental group’s ages and body mass indices were not significantly different from those of the control group.
The researchers compared the bipolar disorder patients’ and control group’s average levels of the biomarkers: C-peptide, ghrelin, glucose-dependent insulinotropic peptide (GIP), glucagonlike peptide-1 (GLP-1), glucagon, insulin, leptin, plasminogen activator inhibitor-1 (PAI-1, total), resistin, and visfatin.
Bipolar disorder patients has significantly lower levels of ghrelin, glucagon, and GLP-1 (P = .018 for ghrelin; P less than .0001 for glucagon; P less than .0001 for GLP-1), and significantly higher levels of GIP than did controls (P less than .0001).
When the bipolar I patients’ biomarker levels were compared with those of the bipolar II patients, no significant differences were found.
Additional findings included negative correlations between a patient’s level of glucagon and numbers of previous manic (r = –0.480; P less than .001), depressive (r = –0.294; P = .026), and any mood episodes (r = –0.403; P = .002). GLP-1 levels also were negatively correlated with the numbers of manic (r = –0.322; P = .015) and any mood episodes (r = –0.274 ; P = .039) experienced by a patient.
“Our findings support the hypothesis that dysregulations in serum glucagon, GLP-1, GIP, and ghrelin might be involved in [bipolar disorder] pathogenesis, particularly in the depressed phase. Moreover, the correlation of glucagon and GLP-1 alterations with number of mood episode recurrences could contribute to the identification of late-stage” bipolar disorder patients, according to Gianluca Rosso, Ph.D., of the University of Torino, Italy, and his colleagues. “Studies in larger samples are needed to confirm these data and to further investigate the common mechanism between mood and metabolic disorders.”
Read the full article here: (J Affect Disord. 2015 Sept 15;184:293-8.)
FROM JOURNAL OF AFFECTIVE DISORDERS
Nonplanning impulsivity linked to low medication adherence in bipolar patients
In euthymic bipolar patients, higher nonplanning impulsivity, defined as a lack of future orientation, was associated with lower medication adherence, according to a study published in the Journal of Affective Disorders.
Lead author Dr. Raoul Belzeaux of Sainte Marguerite Hospital in Marseilles, France, and his associates examined 260 euthymic bipolar patients who were given a questionnaire. Adherence to medication was evaluated by Medication Adherence Rating Scale, and nonplanning impulsivity was measured by Barratt Impulsiveness Scale.
Even after controlling for potential confounding factors, adherence to medication was correlated with nonplanning impulsivity (beta-standardized coefficient = 0.156; P = .015), the authors noted. In addition, path analysis demonstrated only a direct effect of nonplanning impulsivity on adherence to medication.
Read the full article here: (J Affect Disord. 2015 Sep 15;184:60-6 [doi:10.1016/j.jad.2015.05.041]).
In euthymic bipolar patients, higher nonplanning impulsivity, defined as a lack of future orientation, was associated with lower medication adherence, according to a study published in the Journal of Affective Disorders.
Lead author Dr. Raoul Belzeaux of Sainte Marguerite Hospital in Marseilles, France, and his associates examined 260 euthymic bipolar patients who were given a questionnaire. Adherence to medication was evaluated by Medication Adherence Rating Scale, and nonplanning impulsivity was measured by Barratt Impulsiveness Scale.
Even after controlling for potential confounding factors, adherence to medication was correlated with nonplanning impulsivity (beta-standardized coefficient = 0.156; P = .015), the authors noted. In addition, path analysis demonstrated only a direct effect of nonplanning impulsivity on adherence to medication.
Read the full article here: (J Affect Disord. 2015 Sep 15;184:60-6 [doi:10.1016/j.jad.2015.05.041]).
In euthymic bipolar patients, higher nonplanning impulsivity, defined as a lack of future orientation, was associated with lower medication adherence, according to a study published in the Journal of Affective Disorders.
Lead author Dr. Raoul Belzeaux of Sainte Marguerite Hospital in Marseilles, France, and his associates examined 260 euthymic bipolar patients who were given a questionnaire. Adherence to medication was evaluated by Medication Adherence Rating Scale, and nonplanning impulsivity was measured by Barratt Impulsiveness Scale.
Even after controlling for potential confounding factors, adherence to medication was correlated with nonplanning impulsivity (beta-standardized coefficient = 0.156; P = .015), the authors noted. In addition, path analysis demonstrated only a direct effect of nonplanning impulsivity on adherence to medication.
Read the full article here: (J Affect Disord. 2015 Sep 15;184:60-6 [doi:10.1016/j.jad.2015.05.041]).
FROM THE JOURNAL OF AFFECTIVE DISORDERS
Bipolar patients have lower functional exercise capacity than peers
Patients with bipolar disorder have a lower functional exercise capacity than do healthy controls, according to a pilot study published in Psychiatry Research. Researchers found that backward stepwise regression analyses showed that foot pain, low back pain, and depressive symptoms account for 70% of the variance in functional exercise capacity of patients with bipolar disorder
Davy Vancampfort, Ph.D, of the University of Leuven, Belgium, and his associates compared 30 patients with bipolar disorder with 30 healthy controls. All participants performed the 6-minute walk test to assess the functional exercise capacity and were screened for psychiatric symptoms using the Quick Inventory of Depressive Symptomatology and Hypomania Checklist-32. They found patients with bipolar disorder demonstrated a significantly poorer functional exercise capacity (590.8 plus or minus 112.6 m vs. 704.2 plus or minus 94.3 m) than did their peers, with foot and back pain were the most common negative predictors of functional exercise capacity in patients with bipolar disorder.
The authors noted that a multidisciplinary care model that includes improving the functional exercise capacity should be a key target for treatment. “Physical activity interventions delivered by physical therapists may help ameliorate pain symptoms and improve functional exercise capacity,” the authors wrote.
Read the full article here: (Psychiatry Res. 2015 Sept 30;229(1-2):194-9 [doi:10.1016/j.psychres.2015.07.040]).
Patients with bipolar disorder have a lower functional exercise capacity than do healthy controls, according to a pilot study published in Psychiatry Research. Researchers found that backward stepwise regression analyses showed that foot pain, low back pain, and depressive symptoms account for 70% of the variance in functional exercise capacity of patients with bipolar disorder
Davy Vancampfort, Ph.D, of the University of Leuven, Belgium, and his associates compared 30 patients with bipolar disorder with 30 healthy controls. All participants performed the 6-minute walk test to assess the functional exercise capacity and were screened for psychiatric symptoms using the Quick Inventory of Depressive Symptomatology and Hypomania Checklist-32. They found patients with bipolar disorder demonstrated a significantly poorer functional exercise capacity (590.8 plus or minus 112.6 m vs. 704.2 plus or minus 94.3 m) than did their peers, with foot and back pain were the most common negative predictors of functional exercise capacity in patients with bipolar disorder.
The authors noted that a multidisciplinary care model that includes improving the functional exercise capacity should be a key target for treatment. “Physical activity interventions delivered by physical therapists may help ameliorate pain symptoms and improve functional exercise capacity,” the authors wrote.
Read the full article here: (Psychiatry Res. 2015 Sept 30;229(1-2):194-9 [doi:10.1016/j.psychres.2015.07.040]).
Patients with bipolar disorder have a lower functional exercise capacity than do healthy controls, according to a pilot study published in Psychiatry Research. Researchers found that backward stepwise regression analyses showed that foot pain, low back pain, and depressive symptoms account for 70% of the variance in functional exercise capacity of patients with bipolar disorder
Davy Vancampfort, Ph.D, of the University of Leuven, Belgium, and his associates compared 30 patients with bipolar disorder with 30 healthy controls. All participants performed the 6-minute walk test to assess the functional exercise capacity and were screened for psychiatric symptoms using the Quick Inventory of Depressive Symptomatology and Hypomania Checklist-32. They found patients with bipolar disorder demonstrated a significantly poorer functional exercise capacity (590.8 plus or minus 112.6 m vs. 704.2 plus or minus 94.3 m) than did their peers, with foot and back pain were the most common negative predictors of functional exercise capacity in patients with bipolar disorder.
The authors noted that a multidisciplinary care model that includes improving the functional exercise capacity should be a key target for treatment. “Physical activity interventions delivered by physical therapists may help ameliorate pain symptoms and improve functional exercise capacity,” the authors wrote.
Read the full article here: (Psychiatry Res. 2015 Sept 30;229(1-2):194-9 [doi:10.1016/j.psychres.2015.07.040]).
FROM PSYCHIATRY RESEARCH
Family history, life stressors predict age of bipolar onset
A family history of psychiatric disorders and negative life stressors are associated with earlier and later onset of bipolar disorder, respectively, according to Dr. C.S. Thesing of the department of old age psychiatry, VU University Medical Center, Amsterdam.
In a study of 78 patients aged 60 years or older, a family history of psychiatric disorders was significantly associated with early age of illness onset (P less than .01), while negative stressors were associated with a later age of onset (P less than .05). Childhood abuse was not associated with either age of onset or the presence or absence of a family history of psychiatric disorders, reported Dr. Thesing and coauthors.
“Further research should be aimed at exploring both the biological and environmental aspects of [bipolar disorder] together,” the researchers wrote. “Later age at onset was associated with negative stressors prior to the first episode, possibly requiring a clinical emphasis on preventing stressors and/or strengthening patients in their abilities to deal with stressors to prevent new affective episodes,” they concluded.
Read the full study in Journal of Affective Disorders.
A family history of psychiatric disorders and negative life stressors are associated with earlier and later onset of bipolar disorder, respectively, according to Dr. C.S. Thesing of the department of old age psychiatry, VU University Medical Center, Amsterdam.
In a study of 78 patients aged 60 years or older, a family history of psychiatric disorders was significantly associated with early age of illness onset (P less than .01), while negative stressors were associated with a later age of onset (P less than .05). Childhood abuse was not associated with either age of onset or the presence or absence of a family history of psychiatric disorders, reported Dr. Thesing and coauthors.
“Further research should be aimed at exploring both the biological and environmental aspects of [bipolar disorder] together,” the researchers wrote. “Later age at onset was associated with negative stressors prior to the first episode, possibly requiring a clinical emphasis on preventing stressors and/or strengthening patients in their abilities to deal with stressors to prevent new affective episodes,” they concluded.
Read the full study in Journal of Affective Disorders.
A family history of psychiatric disorders and negative life stressors are associated with earlier and later onset of bipolar disorder, respectively, according to Dr. C.S. Thesing of the department of old age psychiatry, VU University Medical Center, Amsterdam.
In a study of 78 patients aged 60 years or older, a family history of psychiatric disorders was significantly associated with early age of illness onset (P less than .01), while negative stressors were associated with a later age of onset (P less than .05). Childhood abuse was not associated with either age of onset or the presence or absence of a family history of psychiatric disorders, reported Dr. Thesing and coauthors.
“Further research should be aimed at exploring both the biological and environmental aspects of [bipolar disorder] together,” the researchers wrote. “Later age at onset was associated with negative stressors prior to the first episode, possibly requiring a clinical emphasis on preventing stressors and/or strengthening patients in their abilities to deal with stressors to prevent new affective episodes,” they concluded.
Read the full study in Journal of Affective Disorders.